A Study to Learn About the Effects of Felzartamab on Daily Living Activities and Its Safety in Adults With Generalized Myasthenia Gravis (gMG) Ages 18 to 80 Years Old (MYAMERGE)
A Phase 2 Multicenter Study Evaluating the Efficacy and Safety of Felzartamab Compared to Placebo in Adults With Generalized Myasthenia Gravis
In this study, researchers will learn more about the effects of felzartamab, also known as BIIB148, in adult participants with generalized myasthenia gravis, also known as gMG. This is a type of autoimmune disease that affects the signals sent between nerve cells and the muscles. An autoimmune disease means the body's immune system attacks its own healthy cells.
In people with gMG, the body's immune system makes abnormal antibodies that affect the signals that can be sent between the muscle and the nerves at the neuromuscular junction. The neuromuscular junction is where the nerve and muscle connect. The most common antibodies made in gMG are those that target 1 of 2 types of proteins - AchR (acetylcholine receptor) and MuSK (muscle-specific tyrosine kinase).
In this study, researchers wanted to learn more about a study drug called felzartamab. Researchers think felzartamab may lower the amount of antibodies against AChR or MuSK and allow signals between muscles and nerves to be sent normally again.
The main goal of the study is to compare the effects of felzartamab to a placebo on symptoms and daily living activities in adult participants with gMG. A placebo looks like the study drug but does not contain any medicine.
The main question researchers want to answer is:
- Does felzartamab increase the ability to perform daily activities after 26 weeks of treatment in participants with AChR antibodies?
Researchers will also learn more about:
- How many participants have adverse events and serious adverse events during the study? Adverse events are health problems that may or may not be caused by the study drug.
- How the body processes felzartamab
- How felzartamab affects the participants' disease severity
- How many participants' bodies make antibodies against felzartamab after treatment
This study will be done as follows:
-
Participants will join the study after signing an informed consent form, also known as an ICF.
-
Participants will be screened to check if they can join the study. Participants will then be assigned to a study group based on the type of antibodies they have.
- If participants have AChR antibodies, they will be randomly assigned to receive either felzartamab or a placebo. Neither the participants nor the researchers will know if participants are getting the study drug or the placebo.
- If participants have MuSK antibodies, they will receive felzartamab. In this group, the participants, study doctor, and study staff know which drug the participant is taking.
-
Both felzartamab and the placebo will be given as an intravenous (IV) infusion, which involves giving the drug into a vein.
-
During the study, participants will have regular clinic visits and phone calls. At the visits, participants will have blood and urine samples taken and will also have their overall health checked. The participants will also be asked questions about how they are feeling and how their gMG is affecting their daily lives.
-
After their last dose, participants will enter a follow-up safety period for more testing and monitoring of their health.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
The primary objective of this study is to evaluate the efficacy of felzartamab in participants with gMG compared with placebo. The secondary objectives of this study are to evaluate the efficacy, safety, pharmacokinetics (PK) of felzartamab and anti-drug antibodies (ADAs) in participants with gMG.
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Fase
Fase
- Fase 2
Contatti e Sedi
Contatto studio
Contatto studio
- Nome: US Biogen Clinical Trial Center
- Numero di telefono: 866-633-4636
- Email: clinicaltrials@biogen.com
Backup dei contatti dello studio
- Nome: Global Biogen Clinical Trial Center
- Email: clinicaltrials@biogen.com
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Key Inclusion Criteria:
- Documented diagnosis of gMG.
- Myasthenia Gravis Foundation of America (MGFA) clinical Classification II to IVa at Screening and Randomization.
- Corticosteroids must be administered orally on a daily or alternate-day schedule; pulse corticosteroid therapy is not permitted. Concomitant treatment with permitted acetylcholinesterase inhibitor (AChEIs) and/or allowed conventional immunosuppressant standard therapy (ISTs) is allowed, provided all therapies meet protocol-defined requirements.
- Participants receiving AChEIs must have been on a stable dose prior to Randomization.
- Participants receiving Azathioprine must be on treatment and a stable dose prior to Randomization.
- Participants receiving other conventional immunosuppressive drugs (e.g., mycophenolate mofetil, mycophenolic acid, methotrexate, cyclosporine, tacrolimus), or other Sponsor-approved therapy) must be on treatment and on a stable dose prior to Randomization.
- Participants should be up to date on all vaccinations in accordance with local country or regional public health authority guidelines, where feasible. Required vaccinations should be completed at least 4 weeks prior to screening, where applicable. A screening period extension may be permitted to allow completion of required vaccinations.
Key Exclusion Criteria:
- MGFA Class I or IVb, or V at Screening.
- History of myasthenic crisis requiring hospitalization, mechanical ventilation, or intensive care unit admission prior to Screening.
- Anticipated need for rescue therapy between Screening and Randomization.
- Congenital myasthenic syndrome, Lambert-Eaton myasthenic syndrome, or any other neuromuscular disorder that could confound the evaluation of gMG.
- Thymectomy for benign thymoma within 12 months prior to Randomization or planned thymectomy during the study.
- Unresected, active or recurrent thymoma.
- History of malignancy within 5 years prior to Screening except for adequately treated in situ carcinoma of the cervix uteri, basal or squamous cell carcinoma or non-melanomatous skin cancer, or other malignancies considered cured with minimal risk of recurrence, as determined by the Investigator.
NOTE: Other protocol-defined Inclusion/Exclusion criteria may apply.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Quadruplicare
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: Cohort 1: Felzartamab or Placebo
Participants will receive multiple intravenous (IV) doses of felzartamab or placebo. |
Administered IV Administered IV
Altri nomi:
|
|
Sperimentale: Cohort 2: Felzartamab
Participants will receive multiple IV doses of felzartamab. |
Administered IV
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Lasso di tempo |
|---|---|
|
Cohort 1: Change From Baseline in Myasthenia Gravis-Activities of Daily Living (MG-ADL) Total Score at Week 26
Lasso di tempo: Baseline, Week 26
|
Baseline, Week 26
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Lasso di tempo |
|---|---|
|
Cohort 1: Change From Baseline in Quantitative Myasthenia Gravis (QMG) Total Score at Week 26
Lasso di tempo: Baseline, Week 26
|
Baseline, Week 26
|
|
Cohorts 1 and 2: Number of Participants With Adverse Events (AEs) and Adverse Events of Special Interest (AESI)
Lasso di tempo: From first dose of study drug up to end of study follow-up (Up to Week 52)
|
From first dose of study drug up to end of study follow-up (Up to Week 52)
|
|
Cohorts 1 and 2: Felzartamab Serum Concentrations Over Time
Lasso di tempo: Predose and at multiple timepoints postdose up to Week 44
|
Predose and at multiple timepoints postdose up to Week 44
|
|
Cohorts 1and 2: Number of Participants with Anti-drug Antibodies (ADAs) Against Felzartamab
Lasso di tempo: Baseline up to Week 52
|
Baseline up to Week 52
|
Collaboratori e investigatori
Sponsor
Sponsor
Investigatori
Investigatori
- Direttore dello studio: Medical Director, Biogen
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Malattie del sistema nervoso
- Neoplasie per sede
- Neoplasie
- Malattie neuromuscolari
- Malattie autoimmuni
- Malattie del sistema immunitario
- Malattie autoimmuni del sistema nervoso
- Malattie Neurodegenerative
- Sindromi Paraneoplastiche, Sistema Nervoso
- Neoplasie del sistema nervoso
- Sindromi paraneoplastiche
- Malattie della giunzione neuromuscolare
- Miastenia grave
- Felzartamab
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- 299MG201
- 2026-527803-94 (Altro identificatore: EU CT Number)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .